Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)

Pulmonary Tuberculosis Clinical Trial

Official title:

A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00944021
• Other study ID #: PA-824-CL-010
• Status: Completed
• Phase: Phase 2
• Start date: August 2009
• Est. completion date: May 2010

Study information

• Verified date: September 2019
• Source: Global Alliance for TB Drug Development
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of PA-824 at 50, 100, 150 and 200 mg per day in adult patients with newly diagnosed, uncomplicated, smear positive tuberculosis (TB). A control group will receive standard TB treatment.

Description:

The planned sample size of 15 participants per treatment group is in keeping with other Phase II trials of this type and accounts for the possibility of up to 3 drop-outs per arm, which based on previous studies of this type conducted at these sites, represents a conservative estimate of the expected drop-out rate.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: May 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Informed Consent

• Body weight between 40 and 90 kg, inclusive.

• Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.

• A chest X-ray compatible with TB.

• Sputum positive

• Adequate volume of sputum

• Female participants of childbearing potential negative serum pregnancy and agree to use birth control

• Male participants must agree to use contraception throughout participation in the trial and for 12 weeks after last dose.

Exclusion Criteria:

• Poor general condition

• Rifampicin-resistant and/or Isoniazid-resistant

• MTB Treatment received within the 3 months prior

• Allergy to the IMP or related substances

• Evidence of extrathoracic TB

• A history of previous TB

• Evidence of serious lung conditions other than TB or uncontrolled obstructive bronchial disease

• History of lens opacity or evidence of lens opacity on slit lamp ophthalmologic examination

• Any evidence of renal impairment

• For males, any evidence or history of abnormality in the reproductive system

• History and/or presence (or evidence) of neuropathy or epilepsy.

• Clinically relevant changes in the ECG

• A history of or current clinically relevant cardiovascular disorder

• Concomitant use of any drug known to prolong QTc interval

• Diabetics using insulin

• Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).

• Any diseases or conditions in which the use of the standard TB drugs or any of their components is contra-indicated, including but not limited to allergy to any TB drug, their component or to the IMP.

• Any disease or conditions in which any of the medicinal products listed in the section pertaining to prohibited medication is used.

• alcohol or drug abuse

• Administration of an IMP prior to Visit 1, within 5 half-lives for that IMP if known. If the half-life of the IMP is unknown within 1 month.

• Pregnant, breast-feeding, or planning to conceive or father a child within twelve weeks of cessation of treatment for males and within one week of cessation of treatment for females.

• Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes

• Any therapeutic agents known to alter any major organ function (e.g., barbiturates, opiates, phenothiazines, cimetidine) within 30 days prior to dosing.

• glucocorticoids within one year prior to dosing.

• HIV infection with helper/inducer T lymphocyte (CD4 cell) count of less than or equal to 300x10-6/L.

• Receiving antiretroviral therapy (ART).

Related Conditions & MeSH terms

• Pulmonary Tuberculosis
• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Drug:
• PA-824
50mg
• PA-824
100mg
• PA-824
150 mg
• Rifafour e-275 mg
275 mg
• PA-824
200 mg

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Global Alliance for TB Drug Development

References & Publications (1)

Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31. d — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).		14 consecutive days of treatment
Secondary	Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).		Two consecutive days of treatment
Secondary	Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).		Days 2-14 of 14 consecutive days of treatment
Secondary	Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14).		Fourteen consecutive days of treatment
Secondary	Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-2).		Two consecutive days of treatment
Secondary	Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 2-14).		Days 2-14 of 14 consecutive days of treatment
Secondary	Pharmacokinetics- Maximum Observed Plasma Concentration (Cmax) (Day 1).		0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment
Secondary	Pharmacokinetics- Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC 0 to Infinity) (Day 1).		0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment
Secondary	Pharmacokinetics- Terminal Elimination Phase Half-life (t1/2) (Day 1).		0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment
Secondary	Pharmacokinetics-Maximum Observed Plasma Concentration (Cmax) (Day 14).		0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12,16, 24, and 30 hours post-dose on Day 14 of 14 consecutive days of treatment
Secondary	Pharmacokinetics- Terminal Elimination Phase Half-life (t1/2) (Day 14).		0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 24 and 30 hours post-dose on Day 14 of 14 consecutive days of treatment

External Links

•   Link